The medical community is closely watching the evolution of Atavistik Bio, a company leveraging a unique metabolic signaling platform to tackle diseases that have long lacked targeted solutions. Led by research originating from the University of Utah, the firm is currently transitioning into a clinical-stage entity with a $160 million Series B war chest. At the heart of their mission is the quest to treat Hereditary Hemorrhagic Telangiectasia (HHT), a condition where patients suffer from fragile, rupture-prone blood vessels that can lead to catastrophic organ failure. By moving beyond conventional drug-binding sites and focusing on the precision of allosteric regulation, this approach represents a significant shift in how we treat rare hematologic and vascular disorders.
The following discussion explores the complexities of developing first-in-class therapies for HHT, the technical advantages of selective AKT1 inhibition, and how AI-driven metabolite screening is reshaping the timeline of drug discovery in the biopharmaceutical sector.
Hereditary hemorrhagic telangiectasia (HHT) currently has no FDA-approved therapies, leaving patients at risk for life-threatening vessel ruptures. How do you prioritize clinical endpoints for a disease lacking regulatory precedent, and what specific challenges arise when measuring the stability of abnormal blood vessels in early human trials?
In a landscape with zero FDA-approved options, we must look at the most debilitating clinical manifestations, which for HHT patients often start with chronic, severe nosebleeds and progress to dangerous gastrointestinal bleeding. Our primary focus is on stabilizing the vascular architecture to prevent these ruptures by targeting the underlying cellular growth signals. The challenge in early trials is that measuring “vessel stability” isn’t as simple as a single blood test; it requires tracking the frequency of bleeding events and using imaging to monitor arteriovenous malformations in major organs. We are specifically looking at how our small molecule, ATV-1601, can normalize the signaling pathways that cause these vessels to become so fragile and prone to failure in the first place.
AKT inhibitors have historically faced toxicity hurdles because they often hit multiple protein subtypes like AKT2. Since targeting AKT1 selectively is intended to improve safety, what specific metrics define a favorable safety profile for chronic use, and how does this selectivity alter the long-term treatment outlook for bleeding disorders?
The historical baggage of AKT inhibitors comes from “off-target” effects, particularly when AKT2 is inhibited, which can lead to significant metabolic issues like hyperglycemia. By designing ATV-1601 to be highly selective for AKT1, we are aiming to hit the primary driver of abnormal vascular cell growth without disrupting the broader metabolic functions regulated by other AKT subtypes. In our Phase 1 cancer trials, we already observed a favorable safety profile that suggests the molecule is well-tolerated enough for the long-term administration required in a chronic condition like HHT. This selectivity is the “north star” of our program, as it allows us to maintain the drug’s efficacy in preventing vessel rupture while avoiding the toxicities that have sidelined previous generations of these inhibitors.
Conventional drug discovery often focuses on active protein pockets, yet allosteric sites offer a different pathway for regulation through metabolite screening and machine learning. How does identifying these alternative binding sites change the timeline of drug discovery, and what steps are involved in validating AI-driven predictions?
Our platform shifts the focus away from the crowded “active” pockets of proteins and toward allosteric sites, which act like natural volume knobs for protein activity. We begin by screening proteins against various metabolites to see how they naturally interact, then we use artificial intelligence and machine learning to decode these complex relationships. This AI-driven approach significantly accelerates the early discovery phase because it identifies hidden vulnerabilities in a protein that traditional high-throughput screening might miss. To validate these predictions, we conduct rigorous physical assays to ensure the small molecules bind exactly where the AI predicted and produce the intended biological “braking” effect on the disease-driving protein.
The race for HHT treatments currently involves diverse modalities, including RNA interference, clustering antibodies, and small molecules. What are the practical trade-offs between systemic liver-targeted therapies and selective receptor blockers, and how might these different mechanisms eventually coexist in a standard of care for patients?
The HHT space is becoming healthily competitive, with Alnylam using RNA interference to target liver proteins like plasminogen and Tectonic Therapeutic using antibodies to block the APJ receptor. Small molecules like ours offer a different advantage: they can often be administered orally and provide systemic distribution that directly reaches the endothelial cells where the vessel malformations occur. While liver-targeted therapies focus on the blood’s ability to maintain clots, our approach and others like Diagonal Therapeutics’ clustering antibodies focus on the structural integrity of the vessels themselves. Ultimately, the standard of care might involve a combination of these approaches, perhaps using a small molecule for daily maintenance and antibodies for more targeted signaling correction.
Existing JAK inhibitors for blood cancers often impact both mutated and non-mutated proteins, leading to significant side effects. How does a molecule designed solely for the JAK2 V617F mutation transform patient outcomes, and what preclinical benchmarks must be met before transitioning this type of program into the clinic?
Current JAK inhibitors are somewhat “blunt instruments” because they inhibit both the healthy JAK2 protein and the mutated V617F version, which leads to dose-limiting toxicities and side effects for patients with myeloproliferative neoplasms. Our goal is to create a molecule that ignores the healthy protein and only binds to the mutated version, which would theoretically allow for higher, more effective dosing with far fewer side effects. Before this can enter the clinic, we must demonstrate in preclinical models that the molecule achieves a high level of “mutant-selective” inhibition without interfering with normal hematopoiesis. This involves extensive testing in cell lines and animal models to prove that the drug can specifically kill the cancer-driving cells while sparing the healthy ones.
This field is seeing a surge in Series B funding extensions and new investor interest despite the rarity of the target diseases. How does this influx of capital impact the competitive strategy for startups, and what internal milestones are most critical for maintaining investor confidence during the transition to clinical testing?
The recent $40 million extension, bringing in heavyweights like RA Capital Management, provides us with a critical buffer to accelerate our clinical timelines without the immediate pressure of constant fundraising. In a competitive field, this capital allows us to move ATV-1601 into HHT trials more aggressively while simultaneously advancing our preclinical blood cancer programs. To maintain the confidence of our investors, who have now committed a total of $160 million in this Series B round alone, we must hit our enrollment targets and demonstrate clear safety data in the initial HHT patient cohorts. Every milestone, from the successful “IND-enabling” studies to the first human dose in a rare disease setting, serves as a proof point for our allosteric discovery platform.
What is your forecast for the treatment landscape of rare bleeding disorders over the next decade?
I predict that the next ten years will see a shift from merely managing symptoms like nosebleeds to using precision medicine that actually “re-normalizes” the vasculature. Within a decade, we will likely have the first approved therapies for HHT, and the standard of care will move toward oral small molecules that patients can take to prevent life-threatening ruptures before they ever occur. We will also see a dramatic reduction in treatment-related toxicities as “mutant-selective” inhibitors for blood cancers become the norm, replacing the older, less specific inhibitors used today. Ultimately, the integration of AI-driven allosteric drug discovery will mean that many “undruggable” rare diseases will finally have targeted options, turning once-fatal conditions into manageable chronic ones.
